Success of Escherichia coli O25b:H4 Sequence Type 131 Clade C Associated with a Decrease in Virulence

Infect Immun. 2020 Nov 16;88(12):e00576-20. doi: 10.1128/IAI.00576-20. Print 2020 Nov 16.

Abstract

Escherichia coli O25b:H4 sequence type 131 (ST131), which is resistant to fluoroquinolones and which is a producer of CTX-M-15, is globally one of the major extraintestinal pathogenic E. coli (ExPEC) lineages. Phylogenetic analyses showed that multidrug-resistant ST131 strains belong to clade C, which recently emerged from clade B by stepwise evolution. It has been hypothesized that features other than multidrug resistance could contribute to this dissemination since other major global ExPEC lineages (ST73 and ST95) are mostly antibiotic susceptible. To test this hypothesis, we compared early biofilm production, presence of ExPEC virulence factors (VFs), and in vivo virulence in a mouse sepsis model in 19 and 20 epidemiologically relevant strains of clades B and C, respectively. Clade B strains were significantly earlier biofilm producers (P < 0.001), carriers of more VFs (P = 4e-07), and faster killers of mice (P = 2e-10) than clade C strains. Gene inactivation experiments showed that the H30-fimB and ibeART genes were associated with in vivo virulence. Competition assays in sepsis, gut colonization, and urinary tract infection models between the most anciently diverged strain (B1 subclade), one C1 subclade strain, and a B4 subclade recombining strain harboring some clade C-specific genetic events showed that the B1 strain always outcompeted the C1 strain, whereas the B4 strain outcompeted the C1 strain, depending on the mouse niches. All these findings strongly suggest that clade C evolution includes a progressive loss of virulence involving multiple genes, possibly enhancing overall strain fitness by avoiding severe infections, even if it comes at the cost of a lower colonization ability.

Keywords: Escherichia coli; ST131; fimbriae; ibeART operon; in vivo virulence; niche adaptation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Biofilms / drug effects
  • Biofilms / growth & development
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / metabolism
  • Disease Models, Animal
  • Escherichia coli / drug effects
  • Escherichia coli / genetics*
  • Escherichia coli / growth & development
  • Escherichia coli / pathogenicity
  • Escherichia coli Infections / microbiology*
  • Escherichia coli Proteins / genetics*
  • Escherichia coli Proteins / metabolism
  • Evolution, Molecular
  • Extraintestinal Pathogenic Escherichia coli / drug effects
  • Extraintestinal Pathogenic Escherichia coli / genetics*
  • Extraintestinal Pathogenic Escherichia coli / pathogenicity
  • Genotype
  • Integrases / genetics
  • Integrases / metabolism
  • Kaplan-Meier Estimate
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism
  • Mice
  • Phenotype
  • Sepsis / microbiology*
  • Urinary Tract Infections / microbiology
  • Virulence / genetics*
  • Virulence Factors / genetics*
  • Whole Genome Sequencing

Substances

  • Anti-Bacterial Agents
  • CusC protein, E coli
  • DNA-Binding Proteins
  • Escherichia coli Proteins
  • Membrane Proteins
  • Virulence Factors
  • fimB protein, E coli
  • Integrases